Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants. Issue 1 (1st January 2021)

• Record Type: Journal Article
• Authors: Zani, Alberto; Caccuri, Francesca; Messali, Serena; Bonfanti, Carlo; Caruso, Arnaldo
• Is Part Of: Emerging microbes & infections. Volume 10:Issue 1(2021)
• Page Start: 1241
• Page End: 1243
• Publication Date: 2021-01-01
• Subjects: SARS-CoV-2 -- variant of concern -- variant of interest -- BNT162b2 vaccine -- neutralizing antibodies; Medical microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 616.9041
• DOI: 10.1080/22221751.2021.1940305
• Languages: English
• ISSNs: 2222-1751

Abstract

ABSTRACT: In this study, we show that BNT162b2 vaccine-elicited antibodies efficiently neutralize SARS-CoV-2 authentic viruses belonging to B.1, B.1.1.7, B.1.351, B.1.525 and P.1 lineages. Interestingly, the neutralization of B.1.1.7 and B.1.525 lineages was significantly higher, whereas the neutralization of B.1.351 and P.1 lineages was robust but significantly lower as compared to B.1 lineage. Following our findings, we consider that the BNT162b2 vaccine offers protection against the current prevailing variants of SARS-CoV-2.